Geode Capital Management
RAPP

Geode Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Geode Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.6M Buy
721,622
+26,888
+4% +$756K ﹤0.01% 1938
2025
Q4 		$21.1M Buy
694,734
+161,331
+30% +$4.46M ﹤0.01% 1977
2025
Q3 		$15.8M Buy
533,403
+200,244
+60% +$3.57M ﹤0.01% 2127
2025
Q2 		$3.79M Buy
333,159
+17,496
+6% +$186K ﹤0.01% 2874
2025
Q1 		$3.17M Buy
315,663
+104,987
+50% +$1.36M ﹤0.01% 2867
2024
Q4 		$3.74M Buy
210,676
+8,928
+4% +$198K ﹤0.01% 2877
2024
Q3 		$4.13M Buy
+201,748
New +$4.34M ﹤0.01% 2860

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Geode Capital Management's RAPP Position: Q1 2026 in Review

Geode Capital Management increased its Rapport Therapeutics (RAPP) stake by 3.9% in Q1 2026, buying an estimated $756K and bringing the position to 721,622 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

Geode Capital Management first reported a position in RAPP in Q3 2024 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Geode Capital Management held 721,622 shares of Rapport Therapeutics worth $22.6M as of Q1 2026.
  • Geode Capital Management bought 26,888 Rapport Therapeutics shares in Q1 2026, an estimated $756K.
  • Rapport Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1938 holding.
  • Geode Capital Management first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.